Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.29)
# 4,023
Out of 4,814 analysts
35
Total ratings
14.81%
Success rate
-35.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.39 | +1,195.34% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $7.92 | +279.03% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $22.52 | +46.54% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $1.23 | +553.06% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $16.93 | +195.33% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $36.06 | -19.58% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.35 | +104.08% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $9.32 | +232.62% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $26.00 | +130.77% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $84.69 | +65.31% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.21 | +314.94% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.25 | +220.00% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $8.60 | +539.53% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $0.96 | +1,247.57% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $11.60 | +115.61% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.41 | +1,133.05% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.74 | +1,049.43% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.39
Upside: +1,195.34%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.92
Upside: +279.03%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $22.52
Upside: +46.54%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $1.23
Upside: +553.06%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $16.93
Upside: +195.33%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $36.06
Upside: -19.58%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.35
Upside: +104.08%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $9.32
Upside: +232.62%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $26.00
Upside: +130.77%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $84.69
Upside: +65.31%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.21
Upside: +314.94%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.25
Upside: +220.00%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $8.60
Upside: +539.53%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $0.96
Upside: +1,247.57%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $11.60
Upside: +115.61%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.41
Upside: +1,133.05%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.74
Upside: +1,049.43%